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A B S T R A C T
Purpose
To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL)
after a risk-adapted treatment strategy that was based on a positive positron emission tomography
scan performed after two doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) cycles
(PET2).
Patients and Methods
Patients with advanced-stage (IIB to IVB) HL were consecutively enrolled. After two ABVD cycles,
PET2 was performed and centrally reviewed according to the Deauville ﬁve-point scale. Patients
with a positive PET2 were randomly assigned to four cycles of escalated bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) followed by
four cycles of standard BEACOPP with or without rituximab. Patients with a negative PET2 con-
tinued ABVD, and those with a large nodal mass at diagnosis ($ 5 cm) in complete remission with
a negative PET at the end of chemotherapy were randomly assigned to radiotherapy or no further
treatment. The primary end point was 3-year PFS.
Results
Of 782 enrolled patients, 150 (19%) had a positive and 630 (81%) a negative PET2. The 3-year PFS of
all patients was 82%. The 3-year PFS of thosewith a positive and negative PET2was 60% and 87%,
respectively (P, .001). The 3-year PFS of patients with a positive PET2 assigned to BEACOPP with
or without rituximab was 63% versus 57% (P = .53). In 296 patients with both interim and post-
ABVD–negative PET who had a large nodal mass at diagnosis, radiotherapy was randomly added
after chemotherapy without a signiﬁcant PFS improvement (97% v 93%, respectively; P = .29). The
3-year overall survival of all 782 patients was 97% (99% and 89% for PET2 negative and positive,
respectively).
Conclusion
The PET-driven switch from ABVD to escalated BEACOPP is feasible and effective in high-risk
patients with advanced-stage HL.
J Clin Oncol 36:454-462. © 2018 by American Society of Clinical Oncology
INTRODUCTION
In the context of randomized clinical trials, patients
with advanced-stage classic Hodgkin lymphoma
(HL) treated with a standard doxorubicin, vin-
blastine, vincristine, and dacarbazine (ABVD)
program achieved a 3- to 5-year progression-free
survival (PFS) that ranged from 61% to 76%,1-7
with a signiﬁcant proportion of treatment failures as
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a result of either refractory or relapsing disease.1,3,8 The use of
a more-intensive regimen, such as escalated bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine, procarbazine,
and prednisone (BEACOPP), has shown superior disease con-
trol, with a 5-year freedom from treatment failure achieved in up
to 90% of patients.9,10 These remarkable results, however, occur
at the cost of an increased hematologic toxicity, a high incidence
of sterility,11-13 and severe late complications/long-term toxic-
ities, including a 5-year cumulative risk of myelodysplastic
syndrome or acute leukemia of 2.2% compared with only 0.4%
for ABVD.14 For these reasons, avoidance of excessive toxicity in
most patients with a risk-adapted strategy is a major treatment
goal. 18F-ﬂuoro-deoxy-D-glucose positron emission tomography
(PET) performed after one15,16 or two17,18 ABVD cycles has
proven effective in predicting treatment outcome of advanced-
stage HL. On the basis of these observations, we launched
a multicenter prospective trial in 2008 aimed to reserve esca-
lated BEACOPP, the most-effective frontline treatment cur-
rently available, for only patients who were at the highest risk of
chemotherapy resistance as deﬁned by a positive early interim PET
scan.
PATIENTS AND METHODS
Study Design and Procedure
This prospective, open-label, phase II study aimed to improve the
overall 3-year PFS of advanced-stage HL by switching from ABVD to
escalated BEACOPP for a positive early interim PET scan. The study was
conducted in accordance with International Conference on Harmoniza-
tion for Good Clinical Practice guidelines and the Declaration of Helsinki.
Written informed consent was obtained before enrollment. The study was
approved by the Italian Pharmacology Agency and by the ethics com-
mittees of each center. The study was registered with the European Clinical
Trials Database and ClinicalTrials.gov.
Patients
Patients had to fulﬁll the following criteria: histopathologic diagnosis
of classic HL, age 18 to 60 years, no previous therapy, Ann Arbor stage IIB
to IVB, measurable International Prognostic Score (IPS), and signed in-
formed consent. Patients were excluded in case of concomitant or pre-
viously treated (, 5 years) neoplasia, psychiatric disorder, impaired cardiac
(ejection fraction , 50%) and renal (creatinine clearance , 60 mL/min)
functions, HIVor any other active uncontrolled infection, pregnancy; and
uncompensated diabetes.
Treatment Plan
After a baseline PET scan, patients were treated with two cycles of
ABVD followed by an early interim PET reevaluation (PET2). Patients
with PET2-positive scans were randomly assigned to receive BEACOPP
as deﬁned by the German Hodgkin Study Group (four cycles of escalated +
four cycles of baseline BEACOPP) with or without the addition of in-
travenous rituximab 375 mg/m2 given on the day 1 of each BEACOPP
course. Patients with a negative PET2 scan continued their standard ABVD
treatment of a total of six cycles. Among them, those with a large nodal
mass (LNM [$ 5 cm]) at baseline and a ﬁnal negative PET restaging scan
were randomly assigned to consolidation radiotherapy (RT [30 Gy]) on
the site of an LNM detected at diagnosis or to no further treatment
(NFT). In ABVD-treated patients, no chemotherapy dose adjust-
ment was recommended on the basis of neutropenia. The relative dose
intensity (RDI) delivered for ABVD and BEACOPP was calculated as
described elsewhere.19,20
PET Imaging and Treatment Response Evaluation
Each patient had to be scanned in the same PET site throughout
the study and to agree to a centralized PETscan review performed by an
independent panel of nuclear medicine experts. Because interpretation
of negative results does not usually require expert review21,22 a central
revision of PET scans was planned only for patients whose PET images
after the ﬁrst two ABVD cycles were deﬁned by the local site as positive
or with a minimal residual uptake. PET2 scans along with scans at
diagnosis were centralized and, hence, automatically distributed to
a panel of three nuclear medicine expert reviewers (A.B., F.F., U.F.) by
the Web platform WIDEN (Web-Based Imaging Diagnosis by Expert
Network) as previously described.21 The interpretation key for PET2
reporting was the Deauville ﬁve-point scale (DS).23 Positive scans had
a score of 4 and 5. The panel was blinded to any clinical data, and
reviewers used their own workstations to score the scans indepen-
dently and remotely according to blinded independent central review
criteria.24
Statistical Analysis
This trial was designed to suggest a beneﬁt, in terms of 3-year PFS,1-7
of a PET response–adapted strategy. With a Simon optimal two-stage
design, an a-error of 5%, a power of 90%, and an expectation to cure of
approximately 85%, a minimum of 155 patients was needed for enroll-
ment. To assess a beneﬁt of rituximab addition to escalated BEACOPP in
patients with PET2-positive scans, with an expected rescue rate of 75%
after rituximab-escalated BEACOPP and of 50% after escalated BEACOPP,
an a-error of 5%, and a power of 80%, 65 patients had to be randomly
assigned per arm. The results of the ﬁrst interim analysis showed that 19%
of patients had positive PET2 scans, so 684 patients had to be enrolled to
reach the required sample size of 130 randomly assigned patients with
PET2-positive scans.
Survival outcomes were analyzed by intention to treat by using the
Kaplan-Meier method and log-rank test. PFS was measured from the date
of registration to the date of ﬁrst appearance of disease progression,
relapse, or death as a result of any cause; overall survival (OS) was
measured from the date of registration to the date of death as a result of
any cause. Predictive factors of PET2 positivity were assessed with logistic
regression, whereas factors that were predictive of PFS and OS were
assessed with Cox proportional hazards regression models. All reported
P values were two-sided, and the conventional 5% signiﬁcance level was
ﬁxed. Statistical analysis was performed with SAS 9.4 software (SAS
Institute, Cary, NC).
RESULTS
From June 2008 to June 2014, 783 patients were enrolled in the
study from 25 Italian centers and one Israeli center. After
registration, one patient was excluded because the revised
histopathology was consistent with a diagnosis of composite
lymphoma. Median age was 31 years (range, 14 to 60 years); 49%
were men; and 36% had stage IIB, 32% stage III, and 32% stage IV
HL. B symptoms were recorded in 81%. The largest diameter of
systemic adenopathy was , 5 cm in 328 patients, between 5 and
7 cm in 140, between 8 and 10 cm in 159, and . 10 cm in 155
patients (Table 1). The median follow-up was 3.6 years (range, 0 to
7.9 years). Two patients died during the ﬁrst two cycles of ABVD as
a result of disease progression and cardiac failure. Thus, 780
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patients underwent PET2 scanning. The entire study ﬂow is shown
in Figure 1.
Clinical Response, Dose Intensity, and Survival
After two cycles of ABVD, 413 of 780 PET2 scans underwent
blinded independent central review with a mean (median) review
time of 71 (48) hours. The reviewers unanimously agreed on 356
scans (86%), whereas with the remaining 57 (14%) scans, the
majority of reviewers (ie, two of three) deﬁned the ﬁnal result. Of
780 patients, 150 (19%) had a positive and 630 (81%) a negative
PET2 scan. Patients with PET2-positive results were more fre-
quently male (57% v 47%; P = .036), had a higher IPS (P, .001),
and had a larger nodal mass (P, .001). Most patients with PET2-
positive results (149 of 150), were randomly assigned to the
escalated BEACOPP program, with 76 patients allocated to re-
ceive only chemotherapy and 72 to receive the rituximab sup-
plement. One patient was not randomly assigned and received
escalated BEACOPP on the basis of medical decision. During the
ﬁrst four escalated BEACOPP cycles, seven patients withdrew
consent and underwent alternative treatment, three patients died
as a result of disease progression (n = 2) and infection (n = 1), one
patient progressed, and two patients stopped treatment as a result
of toxicity. After four escalated BEACOPP cycles, a PET evalu-
ation was performed in 136 patients, and at the end of the study
program, disease progression was registered in 27 of 108 PET-
negative scans compared with 25 of 28 PET-positive scans (Fig 1).
Of the 630 patients with PET2-negative results, 629 con-
tinued with four additional ABVD cycles of whom 545 (86%)
achieved a durable complete response (CR), 81 (13%) experienced
treatment failure, and four withdrew consent. Of the 296 with an
LNM at baseline and a negative ﬁnal PET scan, 148 were randomly
assigned to consolidation RTon the initial nodal site of disease and
148 to NFT.
The RDI in the two initial ABVD cycles was 97%, whereas the
RDI for the additional four ABVD cycles in patients with PET2-
negative results was 96%. For the BEACOPP-treated patients, the
RDIwas 85% (escalated BEACOPP, 85%; escalated BEACOPP with
rituximab, 84%).
By intention-to-treat analysis, 629 of 782 patients remained in
ﬁrst CR, with a 3-year PFS and OS of 82% (95% CI, 79% to 84%)
and 97% (95% CI, 95% to 98%), respectively (Figs 2A and 2B). For
patients with PET2-positive and -negative results, the 3-year PFS
rate was 60% (95% CI, 51% to 68%) and 87% (95% CI, 84% to
89%; Fig 2C), respectively, whereas the 3-year OS rate was 89%
(95% CI, 82% to 93%) and 99% (95% CI, 97% to 99%; Fig 2D),
respectively. The 3-year event-free survival of patients with PET2-
positive and -negative results was identical to the PFS value because
no secondary cancers have been reported so far, and only one late
pulmonary toxicity was observed in a patient treated with ABVD.
No outcome difference was observed for patients allocated to
rituximab-supplemented BEACOPP compared with BEACOPP,
with a CR rate of 65% versus 63%, a 3-year PFS rate of 63% (95%
CI, 50% to 74%) versus 57% (95% CI, 45% to 68%; P = .53), and
a 3-year OS rate of 89% (95% CI, 79% to 95%) versus 90% (95%
CI, 78% to 95%), respectively (Figs 3A and 3B). The outcome of
BEACOPP was signiﬁcantly different when patients with PET2-
positive scans were analyzed according to DS score. In patients with
a DS score of 4 versus 5, the 3-year PFS rate was 73% (95%CI, 62%
to 81%) versus 35% (95% CI, 22% to 49%; P, .001), respectively,
Table 1. Baseline Characteristics of Patients Included in the Study According to PET2 Results
Characteristic All Patients* PET2 Negative PET2 Positive P
No. of patients 782 630 150
Median age (range), years 31 (14-60) 31 (14-60) 30.5 (18-60) .385
$ 50 79 (10.1) 61 (26.5) 17 (11.3) .545
Sex .036
Male 382 (48.9) 297 (47.1) 85 (56.7)
Female 400 (51.1) 333 (52.9) 65 (43.3)
WHO activity index .122
0-1 707 (90.4) 576 (91.4) 131 (87.3)
. 1 73 (9.3) 54 (8.6) 19 (12.7)
Ann Arbor stage .284
II 279 (35.7) 229 (36.3) 50 (33.3)
III 252 (32.2) 208 (33.0) 44 (29.3)
IV 251 (32.1) 193 (30.6) 56 (37.3)
IPS , .001
0-1 286 (36.6) 251 (39.8) 35 (23.3)
2-3 398 (50.9) 311 (49.4) 87 (58.0)
. 3 98 (12.5) 68 (10.8) 28 (18.7)
Large nodal mass, cm , .001
, 5 328 (41.9) 277 (44.0) 49 (32.7)
5-7 140 (17.9) 123 (19.5) 17 (11.3)
8-10 159 (20.3) 117 (18.6) 42 (28.0)
. 10 155 (19.8) 113 (17.9) 42 (28.0)
B symptoms 634 (81.1) 511 (81.1) 121 (80.7) .901
NOTE. Data are presented as No. (%) except where noted.
Abbreviations: IPS, International Prognostic Score; PET2, 18F-ﬂuoro-deoxy-D-glucose positron emission tomography performed after two doxorubicin, vinblastine,
vincristine, and dacarbazine cycles.
*Two patients died before undergoing PET2 scanning.
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and the 3-year OS rate was 92% (95% CI, 84% to 96%) versus 83%
(95% CI, 67% to 92%; P , .001), respectively (Figs 3C and 3D).
In patients with PET-negative results in CR after six ABVD
cycles, the addition of consolidation RT over an LNM detected at
baseline did not translate into a signiﬁcant clinical beneﬁt compared
with patients who did not undergo RT, with a 3-year PFS rate of 97%
(95%CI, 92% to 99%) for RT versus 93% (95%CI, 87% to 96%) for
NFT (P= .29), respectively, and a 3-yearOS rate of 100%versus 99%
(95% CI, 95% to 100%), respectively (Figs 4A and 4B). When the
analysis was limited to patients with an LNM . 10 cm, the 3-year
PFS rate was 94% (95% CI, 82% to 98%) for consolidation RT and
86% (95% CI, 73% to 93%) for NFT (P = .34). The PFS rate of the
260 patients with no LNM at baseline and not randomly assigned to
RT was 92% (95% CI, 88% to 95%).
For patients randomly assigned to receive RT, this consolidation
was omitted only in three of the 15 who did not have a residual mass.
When the analysis was limited to those with residual mass, the
relapse rate was 3% for those assigned to RT versus 6% of those who
were not, with a 3-year PFS rate of 96% (95% CI, 90% to 98%)
versus 93% (95% CI, 86% to 96%), respectively (P = .39). Overall,
the 3-year relapse-free survival rate of patients with PET2-negative
results was 94% (95%CI, 91% to 96%). The PETresults at the end of
six ABVD cycles were positive in 47 (7%) of 630 patients with PET2-
negative results. After salvage treatment, an overall CR was achieved
in 31 (72%) of 43 evaluable patients. A high-dose chemotherapy
program was given to 35 patients who achieved a CR rate of 66%;
71% of them were alive at last follow-up.
Toxicity and Causes of Death
Toxicity was assessed on the basis of National Cancer Institute
Common Terminology Criteria for Adverse Events (version 3.0).
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Fig 1. CONSORT diagram. ABVD, doxorubicin, vinblastine, vincristine, and dacarbazine; alloSCT, allogeneic stem-cell transplantation; autoSCT, autologous stem-cell
transplantation; Bas, baseline; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; CR, complete remission; Esc,
escalated; LNM, large nodal mass; NFT, no further treatment; PD, progressive disease; PET2, 18F-ﬂuoro-deoxy-D-glucose positron emission tomography performed after
ABVD cycles; R, rituximab; RT, radiotherapy.
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During the ﬁrst two ABVD cycles, grade 3 to 4 neutropenia was
recorded in 323 patients (41%). Other toxicities, including GI (grade 3
nausea/vomiting), pulmonary (grade 3 infection), and metabolic
(grade 3 increase of ALTand AST) were recorded in, 1% of patients.
In patients who switched to BEACOPP, grade 3 to 4 hematologic
toxicities were recorded in 76%. Grade 3 and 4 infections occurred in
10% of patients. In patients who continued with ABVD, a grade 3 to 4
hematologic toxicity occurred in 30%and a grade 3 pulmonary toxicity
in 2% (Table 2). Overall, 30 patients (3.8%) died as a result of disease
progression and cardiac failure (n = 2), resistant or progressive disease
(n = 18), transplant-related toxicity (n = 5), infections (n = 4), and
pulmonary ﬁbrosis (n = 1). Between patients with PET2-positive and
-negative results, 16 (11%) of 150 and 12 (2%) of 630 died, respectively.
Predictive Factors of Outcome
By univariable analysis, at diagnosis, predictive factors of
a positive PET2 scan were male sex (P = .037), LNM. 7 cm (P,
.001), and IPS . 1 (P , .001). By multivariable analysis, LNM
(P , .001) and IPS (P , .001) retained their signiﬁcant predictive
value (Appendix Table A1, online only). By multivariable analysis,
factors predictive of PFS were IPS (P = .003) and WHO activity
index (P = .007), whereas the latter was the only factor that affected
OS (P = .019; Appendix Table A2, online only).
DISCUSSION
In this study, we showed that a PET-driven switch from ABVD to
escalated BEACOPP can be safely done in advanced-stage HL.
With an adequate prolonged follow-up, the ﬁnal results of this
trial showed a 3-year PFS of 82%, three points lower than hy-
pothesized (85%) by the study design. The interim treatment
response assessment by PET imaging conﬁrmed its high negative
predictive value for treatment outcome.17,18 The PETscan central
review was feasible and allowed for timely allocation to escalated
BEACOPP only in patients at the highest risk of disease resistance
and recurrence. Of note, the proportion of patients with PET2-
negative scans is highly comparable with that reported by other
investigators.25,26
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Fig 2. (A) Progression-free survival (PFS) and (B) overall survival (OS) for all patients enrolled in the study. (C) PFS and (D) OS according to positive (+) and negative (–)
results for 18F-ﬂuoro-deoxy-D-glucose positron emission tomography performed after two doxorubicin, vinblastine, vincristine, and dacarbazine cycles (PET2).
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As expected, escalated BEACOPP retained its robust anti-
lymphoma activity, particularly in patients with a DS score of 4,
who represented the majority of those with PET2-positive re-
sults. Patients with a DS score of 5 (6% of the study population),
however, had a much-less-favorable response to BEACOPP. This
small subset clearly deserves innovative treatment approaches.27,28
Despite negative PET2 results, a sizeable proportion of patients
(13%), which is higher than reported in previous retrospective
studies,17,18,29 experienced early or late ABVD treatment failure. This
point represents a true limit of the negative predictive value of
interim PET during ABVD treatment, although it was more fre-
quently observed in patients with a higher IPS and stage IV disease.
Despite treatment failure after ABVD, most of these patients were
rescued by salvage high-dose chemotherapy programs. Therefore,
although the clinical parameters related to disease spread and host
response30 remain unable to identify patients with poor prognosis,31
this study conﬁrms that an interim PET is a powerful predictor of
treatment outcome.17,18 In keeping with other prospective
studies,25,26,32 the current results suggest that a PET2-driven
strategy is feasible and that escalated BEACOPP is an effective
salvage treatment of patients with PET2-positive results.25,32
As secondary end points of this trial, we evaluated in two
randomly assigned cohorts the role of rituximab added to BEACOPP
in patients with PET2-positive results and the role of consoli-
dation RT in patients with PET2-negative results and an LNM at
baseline and a negative ﬁnal PET scan after ABVD. Despite en-
couraging preliminary results on CD20 targeting with rituximab
in HL33 and in keeping with the observation of Borchmann
et al,34 no clinical beneﬁt was gained by the combined admin-
istration of rituximab and escalated BEACOPP. In addition and
similarly to what was reported by the German HD15 trial,10 we
found that in patients with PET2-negative scans, consolidation
RT given at the end of ABVD in those with a negative end-of-
treatment PET scan does not provide a signiﬁcant advantage for
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Fig 3. (A) Progression-free survival (PFS) and (B) overall survival of patients with positive results for 18F-ﬂuoro-deoxy-D-glucose positron emission tomography performed
after two doxorubicin, vinblastine, vincristine, and dacarbazine cycles (PET2) randomly assigned to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone (BEACOPP)with orwithout rituximab (R). (C) PFS and (D) OS of patientswith PET2-positive results according to Deauville ﬁve-point scale (DS)
score of 4 or 5.
jco.org © 2018 by American Society of Clinical Oncology 459
Interim Positron Emission Tomography Therapy in Hodgkin Lymphoma
Downloaded from ascopubs.org by Universita Studi Napoli Fed II on February 13, 2019 from 143.225.017.001
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
long-term disease control. This result was independent from the
size of the nodal mass measured at baseline and the residual nodal
enlargement measured at the end of ABVD. Although consoli-
dation RTon LNM was originally included by the Milan group in
the standard ABVD program, this observation underlines the
discriminative role of PET after ABVD to guide consolidation RT
in patients with an LNM. Although, the sample size of this study
was not calculated on the RT substudy and caution is needed
for a wise interpretation, this result is clinically relevant when
considering the long-term safety issues in the treatment strategy
for patients with HL.35,36 The cost-effectiveness of repeat PET
imaging at the end of six ABVD cycles is suggested by the CR rate
achieved by the salvage treatments on the basis of PET results,
even if disease control of a frontline treatment on the basis of
escalated BEACOPP remains superior (PFS rate . 90%) without
the need of PET-guided treatment.34,37 Another secondary study
end point was the toxicity of the overall treatment strategy, which
is in keeping with that already described for ABVD3 and escalated
BEACOPP.9,10 In patients who were switched to BEACOPP,
hematologic toxicity remained signiﬁcantly higher than with
ABVD, even though the treatment-related mortality was low and
mostly a result of second or third salvage treatments.
In conclusion, similar to UK Response Adapted Therapy in
Advanced Hodgkin Lymphoma38 and the American S081625 trials
that share the same trial backbone, the GITIL/FIL HD 0607 trial
demonstrates that a PETresponse–adapted treatment is a feasible,
safe, and effective therapeutic strategy in advanced-stage HL.
Moreover, consolidation RT on an LNM recorded at baseline
could be safely omitted in patients with both interim and end-of-
treatment negative PET scans.
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Fig 4. (A) Progression-free survival (PFS) and (B) overall survival (OS) of patients with negative results for 18F-ﬂuoro-deoxy-D-glucose positron emission tomography
performed after two doxorubicin, vinblastine, vincristine, and dacarbazine cycles (PET2) randomly assigned to radiotherapy (RT) or no further treatment (NFT).
Table 2. Toxicities Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (Version 3.0)
Adverse Event
Highest Grade, No. (%)
Pre-PET2 (n = 782) PET2 Negative (n = 630) PET2 Positive (n = 150)
1-2 3-4 1-2 3-4 1-2 3-4
Blood/bone marrow 105 (13) 323 (41) 109 (17) 189 (30) 4 (3) 114 (76)
GI 48 (6) 6 (1) 38 (6) 6 (1) 17 (11) 0 (0)
Infection 17 (2) 5 (1) 33 (5) 5 (1) 12 (8) 16 (10)
Pulmonary/upper respiratory 6 (1) 2 (, 1) 30 (5) 11 (2) 9 (6) 1 (1)
Constitutional symptoms 4 (1) 0 (0) 18 (3) 1 (, 1) 15 (10) 2 (1)
Vascular 8 (1) 0 (0) 14 (2) 2 (, 1) 10 (7) 2 (1)
Neurology 5 (1) 0 (0) 11 (2) 1 (, 1) 13 (9) 2 (1)
Pain 6 (1) 0 (0) 8 (1) 0 (0) 6 (4) 1 (1)
Dermatology/skin 3 (, 1) 0 (0) 11 (2) 0 (0) 5 (3) 1 (1)
Metabolic/laboratory 5 (1) 6 (1) 1 (, 1) 0 (0) 4 (3) 0 (0)
Cardiac arrhythmia/cardiac general 3 (, 1) 1 (, 1) 4 (1) 2 (, 1) 4 (3) 3 (2)
Musculoskeletal/soft tissue 2 (, 1) 0 (0) 2 (, 1) 3 (, 1) 2 (1) 3 (2)
Allergy/immunology 4 (1) 1 (, 1) 0 (0) 0 (0) 0 (0) 0 (0)
Hepatobiliary/pancreas 0 (0) 3 (, 1) 1 (, 1) 0 (0) 0 (0) 0 (0)
Coagulation 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (1)
Abbreviation: PET2, 18F-Fluoro-deoxy-D-glucose positron emission tomography performed after two doxorubicin, vinblastine, vincristine, and dacarbazine cycles.
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Appendix
Table A1. Univariable and Multivariable Analysis for PET2 Positivity
Univariable Multivariable
OR (95% CI) P OR (95% CI) P
Age, years
, 50 1.00
$ 50 1.19 (0.67 to 2.11) .545
Sex
Female 1.00
Male 1.47 (1.02 to 2.10) .037
WHO activity index
0-1 1.00 1.00
. 1 1.55 (0.89 to 2.70) .124 1.23 (0.69 to 2.19) .480
Stage
II-III 1.00
IV 1.35 (0.93 to 1.96) .114
IPS
0-1 1.00 1.00
. 1 2.18 (1.44 to 3.28) , .001 2.15 (1.42 to 3.28) , .001
Bulky disease, cm
, 7 1.00 1.00
$ 7 2.21 (1.54 to 3.18) , .001 2.22 (1.54 to 3.20) , .001
B symptoms
No 1.00 1.00
Yes 0.97 (0.62 to 1.53) .900 0.81 (0.51 to 1.29) .372
Abbreviations: IPS, International Prognostic Score; OR, odds ratio; PET2, 18F-Fluoro-deoxy-D-glucose positron emission tomography performed after two doxorubicin,
vinblastine, vincristine, and dacarbazine cycles.
Table A2. Multivariable Analysis for Progression-Free Survival and Overall
Survival in All Patients
Progression-Free Survival Overall Survival
HR (95% CI) P HR (95% CI) P
WHO activity index
0-1 1.00 1.00
. 1 1.87 (1.19 to 2.93) .007 2.70 (1.17 to 6.19) .019
IPS
0-1 1.00 1.00
. 1 1.83 (1.23 to 2.73) .003 2.26 (0.85 to 6.01) .101
Bulky disease, cm
, 7 1.00 1.00
$ 7 1.29 (0.92 to 1.80) .143 1.43 (0.69 to 2.95) .334
B symptoms
No 1.00 1.00
Yes 1.26 (0.79 to 2.01) .330 5.76 (0.78 to 42.48) .086
Abbreviations: HR, hazard ratio; IPS, International Prognostic Score.
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